<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01159405</url>
  </required_header>
  <id_info>
    <org_study_id>SeeCure GP-001</org_study_id>
    <nct_id>NCT01159405</nct_id>
    <nct_alias>NCT01374529</nct_alias>
  </id_info>
  <brief_title>The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer</brief_title>
  <official_title>A Pilot Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide (99mTc-GP) in Patients With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SeeCure LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SeeCure LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the biodistribution and dosimetry of single dose of
      99mTc-glycopeptide (99mTc-GP, 20-25 mCi) in 3 different doses of GP (5, 10and 20 mg)in
      patients with breast cancer at pre-chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cohorts of 3 will be treated each at different dose levels and images will be taken at 4 time
      points. For dosimetry estimates, there will be a 20-24 hr time point post-administration of
      99mTc-GP for the first 3 patients. If the biodistribution and dosimetry can be adequately
      quantified without the 20-24 hr scan in 3 patients, then we will eliminate that 4th scan for
      all other patients. Urine and blood samples will be collected at 5 time points, and an
      additional blood and urine sample will be collected for dosimetry analysis at 30~60 min.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the best dose of 99mTc-GP in imaging based upon safety data and tumor-to background (T/B) count density ratios.</measure>
    <time_frame>from 99mTc-GP injection through 30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the optimal time to imaging after injection of 99mTc-GP based upon tumor to-background (T/B) count density ratios at various times.</measure>
    <time_frame>from 99mTc-GP injection through 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>99mTc-GP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>99mTc-GP with SPECT/CT imaging &amp; whole body scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiolabeled (99mTc) GP (Glycopeptide)</intervention_name>
    <description>one injection of Technetium Glycopeptide to yield a target activity of 20-25 mCi to be given by slow IV push (over 3-5 minutes) 5 mg, 10 mg &amp; 20 mg of GP will be injected</description>
    <arm_group_label>99mTc-GP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly diagnosed stage I-IV breast cancer (tumor size

               -  2cm in imaging examinations) who are scheduled to start systemic therapy.

          -  Patients must have histological diagnosis of invasive breast cancer.

          -  Extent of disease will be determined by physical examination and conventional
             radiological studies.

          -  Must be age 18 or older.

          -  ECOG performance status 0-2.

          -  Patients with history of prior malignancies must be disease-free for at least 5 years
             of study entry.

          -  Normal hematological function: WBC &gt; 3000/ul, absolute neutrophil count &gt; 1500/ul,
             platelets &gt; 100,000/ul, and Hgb &gt; 10 gms (transfusion to achieve Hgb &gt; 10 gms is
             acceptable).

          -  Serum total bilirubin &lt; 1.5 mg/dl and SGPT &lt; 1.5 X normal.

          -  Adequate kidney function (creatinine &lt; 1.5 mg/dL).

        Exclusion Criteria:

          -  Patients who received previous chemotherapy for the newly diagnosed breast cancer.

          -  No evidence of primary breast lesion (e.g. T0, Tx).

          -  Pregnant women or sexually active women of childbearing potential who are not
             practicing adequate contraception are excluded.

          -  Patients with myocardial infarction within 6 months of study entry; unstable angina
             pectoris; uncontrolled congestive heart failure; uncontrolled arrhythmia are excluded.

          -  Patients with history of hypersensitivity/allergy to Chitosan/Chitin related shellfish
             foods.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tejal Patel, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Breast Medical Oncologist, Methodist Cancer Center, Houston, Texas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ning Tsao, PhD</last_name>
    <phone>7135719410</phone>
    <email>ning.tsao@seecurellc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chung Wei Huang, Master</last_name>
    <phone>7135719410</phone>
    <email>huangchungwei@seecurellc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Dickman, PhD, MBA, CCRC</last_name>
      <phone>713-441-9777</phone>
      <email>edickman@houstonmethodist.org</email>
    </contact>
    <contact_backup>
      <last_name>Andrea Dotting, M.D</last_name>
      <phone>713-441-8029</phone>
      <email>andotting@houstonmethodist.org</email>
    </contact_backup>
    <investigator>
      <last_name>Tejal Patel, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angel Rodriguez, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Y. Lee, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jenny C-N Chang, M.B.BChir, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2010</study_first_submitted>
  <study_first_submitted_qc>July 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2010</study_first_posted>
  <last_update_submitted>July 29, 2014</last_update_submitted>
  <last_update_submitted_qc>July 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

